Skip to content

Incidence of Trauma Induced Coagulopathy in Patients With Prehospital Administration of Fibrinogen

Incidence of Trauma Induced Coagulopathy in Patients With Prehospital Administration of Fibrinogen

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03572309
Acronym
TICAF
Enrollment
28
Registered
2018-06-28
Start date
2018-06-19
Completion date
2023-05-01
Last updated
2025-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coagulopathy, Hemorrhage, Trauma

Keywords

trauma induced coagulopathy, multiple trauma, fibrinogen

Brief summary

The purpose of the study is to find out the incidence of trauma induced coagulopathy in patients with severe trauma who received fibrinogen prior admission to emergency department during prehospital care.

Detailed description

The study will commence following the Approval by The Ethics Research Committee. All patients admitted to emergency department during the study will be enrolled after fulfilling the inclusion criteria and in the absence of any exclusion criteria. Informed consent will be requested. After admission to emergency department the blood samples will be taken and blood tests and viscoelastic tests will be performed. All data and results will be entered in the study form. Statistical analysis will be performed and incidence of trauma induced coagulopathy estimated. In addition, 28-day mortality and the incidence of thromboembolic complications will be monitored.

Interventions

None listed

Sponsors

Brno University Hospital
CollaboratorOTHER
Masaryk University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* multiple trauma, injury severity score (ISS) ≥16 * administration of fibrinogen in prehospital care * age 18-80 years

Exclusion criteria

* ISS 75 * pregnancy * therapeutic anticoagulation * therapeutic antiaggregation

Design outcomes

Primary

MeasureTime frameDescription
Trauma induced coagulopathyday of enrolmentIncidence of trauma induced coagulopathy

Secondary

MeasureTime frame
28day mortality28 days after enrolment
thromboembolic complications28 days after enrolment

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 26, 2026